Novo Nordisk's Failed Heart Drug Trial Puts Its Diversification Strategy on the Exam Table
Published on 08/02/2026 at 16:23 | Redaktion boerse-global.de
The Danish pharmaceutical giant has entered one of its most consequential stretches in recent memory, with a failed late-stage trial forcing investors to confront a hard question: how much is Novo Nordisk's future worth beyond its blockbuster weight-loss franchise?
The answer, at least for now, has been a sharp markdown. Shares tumbled 8.48 percent on Friday to close at EUR 40.90, leaving the stock 25.45 percent below its 52-week high of EUR 54.86 reached in January. The decline has pushed the company's valuation to roughly 15 times forward earnings — barely half the multiple commanded by arch-rival Eli Lilly — while the dividend yield has climbed to 3.84 percent.
As Novo Nordisk's pipeline faces fresh scrutiny, investors are reminded that risk management isn't just for pharmaceutical giants — it's a daily obligation for every employer. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace hazards properly and stay compliant. Download the free Risk Assessment Toolkit
A Missed Target With a Silver Lining
The trigger was the Phase 3 ZEUS trial, which tested Ziltivekimab, an interleukin-6 inhibitor designed to reduce major cardiovascular events in patients with atherosclerotic disease, chronic kidney disease, and elevated inflammatory markers. Despite enrolling more than 6,300 participants, the drug failed to hit its primary endpoint: the required 15 percent relative risk reduction in heart attacks, strokes, and cardiovascular death was not achieved. Compounding the disappointment, patients receiving the treatment experienced more severe infections than those on placebo.
Novo Nordisk had acquired the drug through its $725 million purchase of Corvidia Therapeutics in 2020, betting it would become a growth engine for the second half of the decade. The setback was felt acutely in Copenhagen, where the shares fell to DKK 306.50.
There is, however, a nuance the market has largely overlooked. The drug did achieve its biological objective — it inhibited the IL-6 signaling pathway as designed. The problem was that this biological effect did not translate into clinical benefit for patients. That distinction matters for the two remaining cardiovascular trials of Ziltivekimab, HERMES and ARTEMIS, which are studying the drug in heart failure patients and in patients following acute heart attacks, respectively. Results from both are expected in the first half of 2027.
Analysts Split on Whether the Selloff Was Justified
Wall Street's reaction has been notably divided. JPMorgan's Richard Vosser called the share price response understandable, estimating the lost revenue potential in the billions of dollars, though he saw only a moderate impact on consensus estimates. Citi, by contrast, argued the selloff was overdone — the bank had assigned Ziltivekimab a risk-adjusted peak sales potential of roughly $1.7 billion, representing just 3 percent of the company's valuation. UBS's Matthew Weston struck a middle ground, noting the drug accounted for only 1.7 percent of Novo Nordisk's net present value, yet still expects a market reaction two to three times larger than the pure valuation effect, arguing the failure amplifies pressure on the broader pipeline. Mizuho's Jared Holz described the data as a disappointment that could weigh on sentiment across Novo's non-obesity programs. BMO went further, calling positive outcomes for the remaining studies unlikely.
The divergence is reflected in analyst ratings: of the 26 analysts covering the stock, 18 recommend "Hold," and the average price target implies just 4.45 percent upside from pre-crash levels.
A Broader Pattern of Setbacks
The ZEUS failure lands at a delicate moment for Novo Nordisk, which has spent much of the past year managing expectations. The company had already tempered enthusiasm around CagriSema, its next-generation obesity candidate, after a trial showed 23 percent weight reduction versus the 25 percent some had hoped for. In June, chief medical officer Filip Krag Knop cautioned that the market was overly fixated on the weight-loss percentage as a standalone metric.
The legal front adds another layer of uncertainty. A US class action lawsuit accuses Novo Nordisk of misleading investors about the CagriSema trial, and a federal judge recently ruled that parts of the case can proceed, finding investors had plausibly argued that statements about tolerability and trial design were misleading. The company denies the allegations and has vowed to defend itself vigorously. Separately, a dispute with Hims & Hers over an alleged copycat version of the Wegovy pill remains unresolved.
While Novo Nordisk navigates legal challenges, UK employers face their own compliance risks — especially around hazardous substances. A free COSHH toolkit provides 43 customisable templates and checklists to help you meet your legal duty to assess risks from dangerous materials. Get the free COSHH Toolkit
What Tuesday's Numbers Will Reveal
The immediate focus now shifts to August 5, when Novo Nordisk releases its first-half results. The consensus calls for earnings per share of $0.81, a 16.5 percent decline from the $0.97 reported in the prior-year period. The report will offer the first detailed look at how pricing pressure in the obesity market, the rollout of the Wegovy tablet, and competitive dynamics with Eli Lilly are shaping the business.
Management has confirmed its operating guidance for the current fiscal year remains intact, though a non-cash impairment charge will hit the third quarter. The stock currently sits almost exactly at its 50-day moving average of EUR 40.90, and the 14-day relative strength index of 41.8 suggests the market has digested the news without tipping into panic.
The strategic stakes, however, extend well beyond the next earnings print. Ziltivekimab was meant to demonstrate that Novo Nordisk could diversify beyond GLP-1 therapies — that its scientific engine could produce winners in entirely different therapeutic areas. Its failure raises uncomfortable questions about how much of the company's future value rests on a single, increasingly competitive franchise. Tuesday's commentary on the pipeline and diversification strategy will be scrutinized for signs that management has a credible answer.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
